In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?

In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?

Bibliographic Details
Main Authors:	Gabriel T. Cuba, Paulo H.D. Santos, Antonio C.C. Pignatari, David P. Nicolau, Carlos R.V. Kiffer
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Brazilian Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867022000435

Similar Items

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022-04-01)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
by: Kuti JL, et al.
Published: (2018-05-01)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
by: Yuhang Wang, et al.
Published: (2022-10-01)

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
by: Mohsen Yazdanian, et al.
Published: (2023-03-01)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
by: Xi-kang Tang, et al.
Published: (2022-03-01)

Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Pseudomonas aeruginosa
by: Hai Yang, et al.
Published: (2023-12-01)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
by: Molinaro M, et al.
Published: (2018-09-01)

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
by: Sameh Seyam, et al.
Published: (2022-06-01)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i>
by: Sara Mahmoud Farhan, et al.
Published: (2021-11-01)

Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens
by: Pignatari Antonio CC, et al.
Published: (2011-10-01)

Enhanced effect of Amikacin in conjugation with gold nanopartcles as a carrier to kill Pseudomonas aeruginosa
by: Afsaneh Emameian, et al.
Published: (2020-12-01)

The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa
by: Wedad M. Nageeb, et al.
Published: (2022-01-01)

The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa.
by: Wedad M Nageeb, et al.
Published: (2022-01-01)

Evaluation of the combinatory effect of Ecalta each with Levofloxacin and Amikacin on preformed biofilm of Pseudomonas aeruginosa
by: Sara G. Issa, et al.
Published: (2020-12-01)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
by: Ana Motos, et al.
Published: (2023-02-01)

Study of the antimicrobial effect of Amikacin encapsulated in Mesoporous Silica nanoparticles against Pseudomonas aeruginosa and Staphylococcus aureus
by: Somayeh Hosseini khomeirani, et al.
Published: (2017-04-01)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
by: Feiyang Zhang, et al.
Published: (2021-12-01)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
by: Minyon L. Avent, et al.
Published: (2022-06-01)

Killing Dynamics of Carbapenems against Pseudomonas aeruginosa Harboring Varied Determinants of Carbapenem Resistance
by: Viga Rolly, et al.
Published: (2020-06-01)

Combination of AS101 and Mefloquine Inhibits Carbapenem-Resistant Pseudomonas aeruginosa in vitro and in vivo
by: Li R, et al.
Published: (2023-11-01)

Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema
by: Tzu-Ting Chen, MS, et al.
Published: (2022-06-01)

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro
by: Lan Yu, et al.
Published: (2019-12-01)

Antibiotic Sensitivity Pattern of Carbapenem-Resistant Pseudomonas Aeruginosa
by: Fatima Ali, et al.
Published: (2023-02-01)

Distinctive Regulation of Carbapenem Susceptibility in Pseudomonas aeruginosa by Hfq
by: Elisabeth Sonnleitner, et al.
Published: (2020-05-01)

<it>In vitro </it>antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-<it>β</it>-lactamase-producing <it>Pseudomonas aeruginosa</it>
by: Oie Shigeharu, et al.
Published: (2009-08-01)

35: EVALUATING MONO- AND COMBINATION THERAPY OF MEROPENEM AND AMIKACIN AGAINST PSEUDOMONAS AERUGINOSA BACTEREMIA IN THE HOLLOW-FIBER INFECTION MODEL
by: Minyon Avent, Dr, et al.
Published: (2022-11-01)

High mortality outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a Brazilian pediatric oncology hospital
by: Milene Gonçalves Quiles, et al.
Published: (2017-03-01)

Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa
by: Ana Lúcia Lei Munhoz Lima, et al.

Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa
by: Anneke van der Zee, et al.
Published: (2018-09-01)

Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore
by: Jocelyn Qi-Min Teo, et al.
Published: (2021-01-01)

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
by: Mona Ahmed Ammar, et al.
Published: (2018-01-01)

In vitro activity of biapenem and other carbapenems against Russian clinical isolates of Pseudomonas aeruginosa, Acinetobacter spp., and Enterobacterales
by: Kozlov R.S., et al.
Published: (2021-09-01)

Socioeconomic burden of bloodstream infections caused by carbapenem-resistant and carbapenem-susceptible Pseudomonas aeruginosa in China
by: Kai Yang, et al.
Published: (2021-09-01)

The glycopatterns of Pseudomonas aeruginosa as a potential biomarker for its carbapenem resistance
by: Jing Dang, et al.
Published: (2023-12-01)

Aminoglycoside-modifying Enzymes in Carbapenem-resistant Pseudomonas aeruginosa Clinical Isolates
by: Yeliz TANRIVERDİ ÇAYCI, et al.
Published: (2022-10-01)

Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China
by: Yan-Yan Hu, et al.
Published: (2019-10-01)

Molecular characterisation of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Nepal
by: Toshihiro Takahashi, et al.
Published: (2021-09-01)

Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in highcomplexity hospital
by: Ana Milda Karsten Baumgart, et al.
Published: (2010-09-01)

Emergence of carbapenem resistance due to the novel insertion sequence ISPa8 in Pseudomonas aeruginosa.
by: Randal C Fowler, et al.
Published: (2014-01-01)

Outbreak investigations after identifying carbapenem-resistant Pseudomonas aeruginosa: a systematic review
by: Andrea C. Büchler, et al.
Published: (2023-04-01)